Postmenopausal hormone therapy in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil): who still uses it?

Imagem de Miniatura
Arquivos
art_AQUINO_Postmenopausal_hormone_therapy_in_the_Brazilian_Longitudinal_Study_2016.PDF (312.18 KB)
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2016
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY-BLACKWELL
Autores
AQUINO, Estela M. L.
ALMEIDA, Maria-da-Conceicao C.
MENEZES, Greice M. S.
FIGUEIREDO, Roberta Carvalho de
MENGUE, Sotero Serrate
FONSECA, Maria de Jesus M. da
GABRIELLI, Ligia
Citação
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, v.25, n.6, p.609-617, 2016
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
PurposeWe aim to investigate the patterns of hormone therapy (HT) use and associated factors in women participating in the Brazilian Longitudinal Study of Adult Health. MethodsThis study included 3281 naturally menopausal women of 40 to 74years of age at enrollment to the Brazilian Longitudinal Study of Adult Health study, who answered questions regarding their use and discontinuation of HT. Prevalence rates of current and previous HT use were calculated, and a multinomial logistic regression model was constructed to simultaneously analyze the associated factors. ResultsThe prevalence of HT use increased from 1995 onwards, peaking at 55.7% in 1997. A sharp decline occurred in the decade beginning in 2000, reaching 11.1% at the study baseline interview (2008-2010). Current use was associated with being 60years of age (Relative Risk Ratio (RRR): 1.81; 95%CI: 1.10-2.96), divorced (RRR: 1.72; 95%CI: 1.14-2.60), or married (RRR: 2.09; 95%CI: 1.41-3.10); having a university education (RRR: 1.66; 95%CI: 1.14-2.40) or postgraduate degree (RRR: 2.45; 95%CI: 1.80-3.35); and having private health insurance (RRR: 2.86; 95%CI: 2.00-4.09). Body mass index 30kg/m(2) was inversely associated with HT use (RRR: 0.37; 95%CI: 0.26-0.53) as was the presence of at least one contraindication to HT use (RRR: 0.63; 95%CI: 0.44-0.89). Of the current users 60years of age, 79.1% had been using HT for at least 5years, and 73.6% had been menopausal for at least 10years. ConclusionAlthough the use of HT has declined in Brazil, the women who continue using it are largely exceeding evidence-based limits of age, time since menopause, and time of use.
Palavras-chave
postmenopause, hormone therapy, inappropriate use, drug use, developing countries, pharmacoepidemiology, pharmacoepidemiology
URI
https://observatorio.fm.usp.br/handle/OPI/16096
Referências
  1. Aquino EML, 2012, AM J EPIDEMIOL, V175, P315, DOI 10.1093/aje/kwr294
  2. Aranha Renata Nunes, 2004, Cad. Saúde Pública, V20, P100, DOI 10.1590/S0102-311X2004000100024
  3. Banks E, 2003, LANCET, V362, P419
  4. Barrett-Connor E, 2000, J WOMEN HEALTH GEN-B, V9, P633, DOI 10.1089/15246090050118161
  5. Beck-Peccoz P, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-9
  6. Beral V, 1997, LANCET, V350, P1047
  7. Bernis C, 2007, MENOPAUSE, V14, P777, DOI 10.1097/gme.0b013e31803020ff
  8. Brasil. Agencia Nacional de Vigilancia Sanitaria, 2010, DIAGN SIT PROM MED U
  9. Brasil. Ministerio da Saude Secretaria de Ciencia TeIE, 2008, DDAFEI ESTR REL NAC
  10. Brunoni AR, 2013, J AFFECT DISORDERS, V151, P71, DOI 10.1016/j.jad.2013.05.054
  11. Clapauch Ruth, 2005, Arq Bras Endocrinol Metab, V49, P449, DOI 10.1590/S0004-27302005000300018
  12. Connelly MT, 2000, J GEN INTERN MED, V15, P542, DOI 10.1046/j.1525-1497.2000.03499.x
  13. de Villiers TJ, 2013, MATURITAS, V74, P391, DOI 10.1016/j.maturitas.2013.02.001
  14. Diniz SG, 2009, J HUM GROWTH DEV, V19, P313, DOI 10.1590/S0104-12822009000200012
  15. Faber A, 2005, BRIT J CLIN PHARMACO, V60, P641, DOI 10.1111/j.1365-2125.2005.02502.x
  16. Grady D, 2002, JAMA-J AM MED ASSOC, V288, P49, DOI 10.1001/jama.288.1.49
  17. Gravena Angela Andréia França, 2013, Rev. Bras. Ginecol. Obstet., V35, P178, DOI 10.1590/S0100-72032013000400008
  18. Guay MP, 2007, PHARMACOEPIDEM DR S, V16, P17, DOI 10.1002/pds.1273
  19. Hersh AL, 2004, JAMA-J AM MED ASSOC, V291, P47, DOI 10.1001/jama.291.1.47
  20. Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605
  21. Lazar F, 2007, MATURITAS, V56, P129, DOI 10.1016/j.maturitas.2006.06.022
  22. Lundberg V, 2004, MATURITAS, V48, P39, DOI 10.1016/j.maturitas.2003.08.006
  23. Moyer VA, 2013, ANN INTERN MED, V158, P47, DOI 10.7326/0003-4819-158-1-201301010-00553
  24. Mueller KA, 2003, MATURITAS, V45, P137, DOI 10.1016/S0378-5122(03)00145-2
  25. Pinto Neto AM, 2002, CAD SAUDE PUBLICA, V18, P121, DOI [10.1590/S0102-311X2002000100013, DOI 10.1590/S0102-311X2002000100013]
  26. Olmos RD, 2015, BRAZ J MED BIOL RES, V48, P751, DOI 10.1590/1414-431X20154445
  27. Oppermann K, 2012, MENOPAUSE, V19, P355, DOI 10.1097/gme.0b013e31822ba026
  28. Paim J, 2011, LANCET, V377, P1778, DOI 10.1016/S0140-6736(11)60054-8
  29. Pedro AO, 2002, REV SAUDE PUBL, V36, P484, DOI [10.1590/S0034-89102002000400015, 10.1590/s0034-89102002000400015]
  30. Pedro AO, 2003, REV SAUDE PUBL, V37, P735, DOI 10.1590/s0034-89102003000600008
  31. Pereira AS, 2005, MATURITAS, V51, P146, DOI 10.1016/j.maturitas.20045.06.018
  32. Polisseni Álvaro Fernando, 2009, Rev. Bras. Ginecol. Obstet., V31, P28, DOI 10.1590/S0100-72032009000100006
  33. Ravdin PM, 2007, NEW ENGL J MED, V356, P1670, DOI 10.1056/NEJMsr070105
  34. Ringa V, 2010, FERTIL STERIL, V94, P1387, DOI 10.1016/j.fertnstert.2009.07.1001
  35. Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/JAMA.288.3.321
  36. Rozenfeld Suely, 2007, Ciênc. saúde coletiva, V12, P437, DOI 10.1590/S1413-81232007000200020
  37. Santen RJ, 2010, J CLIN ENDOCR METAB, V95, pS7, DOI 10.1210/jc.2009-2509
  38. Santos IS, 2000, REV SAUDE PUBL, V34, P603, DOI 10.1590/S0034-89102000000600007
  39. Sclowitz Iândora Krolow Timm, 2005, Cad. Saúde Pública, V21, P469, DOI 10.1590/S0102-311X2005000200013
  40. Sievert LL, 2008, MATURITAS, V59, P7, DOI 10.1016/j.maturitas.2007.11.001
  41. Silva Filho Carlos Rodrigues da, 2005, Rev Saude Publica, V39, P333
  42. Silva Filho Euvaldo Angeline da, 2008, Rev. Bras. Ginecol. Obstet., V30, P113
  43. Silveira IL, 2007, REV BRAS GINECOL OBS, V29, P415, DOI [10.1590/S0100-72032007000800006, DOI 10.1590/S0100-72032007000800006]
  44. Domingues RMSM, 2014, CAD SAUDE PUBLICA, V30, DOI 10.1590/0102-311X00105113
  45. Stefanick Marcia L, 2005, Am J Med, V118 Suppl 12B, P64, DOI 10.1016/j.amjmed.2005.09.059
  46. Valadares AL, 2008, REV ASSOC MED BRAS, V54, P299, DOI 10.1590/S0104-42302008000400013
  47. Vieira FS, 2010, REV PANAM SALUD PUBL, V27, P149
  48. Vigeta Sônia Maria Garcia, 2004, Cad. Saúde Pública, V20, P1682, DOI 10.1590/S0102-311X2004000600027
  49. Wender MCO, 2014, CONSENOS BRASILEIRO
  50. World Health Organization Scientific Group, 1996, WHO TECHN REP SER
  51. Zahar Sílvia E. V., 2005, Rev. Assoc. Med. Bras., V51, P133, DOI 10.1590/S0104-42302005000300012
  52. [Anonymous], 2012, MENOPAUSE, V19, P257, DOI 10.1097/GME.OB013E31824B970A

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - LIM/20